- Our Hepatitis C Commissioning Toolkit features a template service specification for including measures on hepatitis… https://t.co/BAQ7yGScyA — 4 days 8 hours ago
- DAA medications for hepatitis C associated with reduced risk of mortality and liver cancer, finds new study in… https://t.co/PnJn6tDW74 — 6 days 6 hours ago
- RT @NO_hep: Did you know that #hepC is curable? Hear from @philipcbaldwin and his personal story of triumph over hepatitis C here via @Huf… — 1 week 1 day ago
- Did you miss the latest @HCVAction e-update last week? Catch up here with updates on new research on hep C preventi… https://t.co/0WpjiDvCNt — 1 week 4 days ago
- New to the @HCVAction resource library: @HCVCoalition's summary report of their December 2018 roundtable meeting on… https://t.co/Slp2kV4Eb2 — 1 week 6 days ago
Comments
Collaboration request
Dear All,
I am a researcher at the University of Rome Tor Vergata and a lecturer in Health Economics at Kingston University. I am currently participating to a research study sponsored by the Italian Public Health Institute (Istituto Superiore di Sanita' - ISS) monitoring the uptake of the Hepatitis C, DAA-treated patients in some European Countries (Italy, Spain, Romania and, possibly England). PHE recently published a report drawn from the English database, which reports cumulatively the data that we are looking for (https://www.gov.uk/government/publications/hepatitis-c-treatment-monitor... and https://www.gov.uk/government/publications/hepatitis-c-in-the-uk). However, we are struggling to retrieve the stratification per year between 2014 and 2018 that is not contained in the document.
Would you be so kind as to assist me with that and suggest where I can find the remaining information?
I have prepared a table (15 numbers needed) reporting the data I have and the columns I need to fill in. I recognise that this could involve additional queries, and we are ready to finance the administrative costs related to the extraction of the additional data.
Furthermore, I would really appreciate the possibility to have a conversation aimed to explore the possibilities of conjoint research. We would, of course, reciprocate the access to our database exclusively to PHE. This is the first article published with Italian HCV patients sample that we would like to reproduce for all other countries (Marcellusi A, Viti R, Kondili LA, Rosato S, Vella S, Mennini FS; PITER Collaborating group available at www.progettopiter.it. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. Pharmacoeconomics. 2019 Feb;37(2):255-266).
A final question refers to the price per treatment of DAAs during the years. In Italy, we assume an average drug cost per patient of € 25,000 in 2015, € 15,000 in 2016, € 9,000 in 2017 and € 6,000 in 2018. Do you know where I can find this information?
I thank you in advance for your courtesy and I’m sorry if you are not the right person for my question,
Regards
Andrea
Andrea Marcellusi PhD
Economic Evaluation and HTA (EEHTA)
Faculty of Economics
University of Rome "Tor Vergata"
Via Columbia, 2
00133, Rome
Italy
Lecturer in Health Economics
Department of Accounting Finance and Informatics
Room KHBS2013, Kingston Business School,
Kingston University,
Kingston Hill,
Kingston upon Thames KT2 7LB
London
M +39 3492748592
andrea.marcellusi@uniroma2.it
a.marcellusi@kingston.ac.uk